225 related articles for article (PubMed ID: 10610197)
1. Consensus statement of the Canadian MS CLinics Network on: the use of disease modifying agents in multiple sclerosis.
Oger J; Freedman M
Can J Neurol Sci; 1999 Nov; 26(4):274-5. PubMed ID: 10610197
[No Abstract] [Full Text] [Related]
2. Editorial: the pitfalls of combination therapy.
Vermersch P
Int MS J; 2006 Nov; 13(3):75-6. PubMed ID: 17101074
[No Abstract] [Full Text] [Related]
3. Interferon beta and glatiramer acetate therapy.
McGraw CA; Lublin FD
Neurotherapeutics; 2013 Jan; 10(1):2-18. PubMed ID: 23264098
[TBL] [Abstract][Full Text] [Related]
4. Multiple sclerosis disease-modifying therapy and pregnancy.
Miller AE
Mult Scler; 2016 May; 22(6):715-6. PubMed ID: 27207870
[No Abstract] [Full Text] [Related]
5. Concomitant therapy for multiple sclerosis.
Stuart WH; Vermersch P
Neurology; 2004 Dec; 63(11 Suppl 5):S28-34. PubMed ID: 15596733
[TBL] [Abstract][Full Text] [Related]
6. [Disease modifying drugs in multiple sclerosis and pregnancy].
Tur C; Tintoré M; Aguilera C
Med Clin (Barc); 2012 Sep; 139(7):316-8. PubMed ID: 22743277
[No Abstract] [Full Text] [Related]
7. Multiple sclerosis: monotherapy rules.
Hauser SL; Josephson SA; Johnston SC
Ann Neurol; 2013 Mar; 73(3):A5-6. PubMed ID: 23596013
[No Abstract] [Full Text] [Related]
8. [Logistics and description of treatment technology (the protocol for using disease modifying drugs--DMD)].
Federal service on surveillance in healthcare and social development (Roszdravnadzor)
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):93-8. PubMed ID: 21916163
[No Abstract] [Full Text] [Related]
9. [The technology of treatment of multiple sclerosis with long-term immunomodulating drugs (disease modifying drugs--DMD)--beta-interferons and glatiramer-acetate].
Federal service on surveillance in healthcare and social development (Roszdravnadzor)
Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):86-92. PubMed ID: 21916162
[TBL] [Abstract][Full Text] [Related]
10. Comment on Shuhaibar et al.: Favourable effect of immunomodulator therapy on bone mineral density in multiple sclerosis.
Kampman MT; Steffensen LH
Ir J Med Sci; 2009 Jun; 178(2):235-6; author reply 237-8. PubMed ID: 19184608
[No Abstract] [Full Text] [Related]
11. Disease modifying treatment in multiple sclerosis.
Fuller GN; Bone I
J Neurol Neurosurg Psychiatry; 2001 Dec; 71 Suppl 2(Suppl 2):ii20-1. PubMed ID: 11701780
[No Abstract] [Full Text] [Related]
12. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines.
Goodin DS; Frohman EM; Garmany GP; Halper J; Likosky WH; Lublin FD; Silberberg DH; Stuart WH; van den Noort S;
Neurology; 2002 Jan; 58(2):169-78. PubMed ID: 11805241
[No Abstract] [Full Text] [Related]
13. Current approved options for treating patients with multiple sclerosis.
Rizvi SA; Agius MA
Neurology; 2004 Dec; 63(12 Suppl 6):S8-14. PubMed ID: 15623672
[TBL] [Abstract][Full Text] [Related]
14. [Possibilities and limits of immunotherapy in multiple sclerosis. Inflammatory and degenerative aspects of the disease require a new pathogenetic concept].
Kornhuber ME; Zierz S
Nervenarzt; 2003 Jun; 74(6):537-8; discussion 539. PubMed ID: 12799792
[No Abstract] [Full Text] [Related]
15. The UK Risk-Sharing Scheme for interferon-beta and glatiramer acetate in multiple sclerosis. Outcome of the year-6 analysis.
Duddy M; Palace J
Pract Neurol; 2016 Feb; 16(1):4-6. PubMed ID: 26430247
[No Abstract] [Full Text] [Related]
16. Confusion over UK beta-interferon "trials".
Dean M
Lancet; 2001 Nov; 358(9293):1619. PubMed ID: 11716901
[No Abstract] [Full Text] [Related]
17. Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature.
Mahurkar S; Suppiah V; O'Doherty C
Autoimmun Rev; 2014 Feb; 13(2):178-86. PubMed ID: 24189284
[TBL] [Abstract][Full Text] [Related]
18. [Additional indicators of the assessment of efficacy of disease modifying drugs (preliminary results)].
Iakushina TI; Lizhdvoĭ VIu; Vasilenko IA; Andriukhina OM; Kotov SV
Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(2 Pt 2):61-5. PubMed ID: 23528596
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacological treatment of multiple sclerosis].
Myhr KM
Tidsskr Nor Laegeforen; 2010 Mar; 130(5):490-2. PubMed ID: 20224616
[TBL] [Abstract][Full Text] [Related]
20. The use of interferon Beta and glatiramer acetate in multiple sclerosis.
Goodin DS
Semin Neurol; 2013 Feb; 33(1):13-25. PubMed ID: 23709209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
